NQO1 expression correlates inversely with NFκB activation in human breast cancer

Breast Cancer Research and Treatment

Volumn 132, Issue 3, 2012, Pages 955-968

  Jamshidi, Maral ^a   Bartkova, Jirina ^b   Greco, Dario ^a   Tommiska, Johanna ^a,c   Fagerholm, Rainer ^a   Aittomäki, Kristiina ^a   Mattson, Johanna ^a   Villman, Kenneth ^d   Vrtel, Radek ^e   Lukas, Jiri ^b   Heikkilä, Päivi ^a   Blomqvist, Carl ^a   Bartek, J ^b,e   Nevanlinna, Heli ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c UNIVERSITY OF HELSINKI   (Finland)

^d ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^e PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Breast cancer; Chemotherapy; Metastasis; NF B; NQO1

Indexed keywords

ANTHRACYCLINE; DOCETAXEL; ESTROGEN RECEPTOR; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; KI 67 ANTIGEN; METHOTREXATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (QUINONE); SYNAPTOTAGMIN I; NQO1 PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORPHOLOGY; CANCER SURVIVAL; DRUG RESPONSE; GENE EXPRESSION PROFILING; GENETIC VARIABILITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIPOGENESIS; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; METASTASIS; MICROARRAY ANALYSIS; NUCLEAR LOCALIZATION SIGNAL; OVERALL SURVIVAL; OXIDATION REDUCTION POTENTIAL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STEROID METABOLISM; SURVIVAL TIME; BREAST TUMOR; CELL NUCLEUS; DNA MICROARRAY; FEMALE; GENETICS; LUNG CARCINOMA; METABOLISM; MORTALITY; PAGET NIPPLE DISEASE; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CELL NUCLEUS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; NAD(P)H DEHYDROGENASE (QUINONE); NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS;

EID: 84865165004     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1629-5     Document Type: Article

References (58)

1. *2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 40:844-853
2. Traver RD, Siegel D, Beall HD, Phillips RM, Gibson NW, Franklin WA et al (1997) Characterization of a polymorphism in NAD (P) H: quinone oxidoreductase (DT-diaphorase). Br J Cancer 75:69-75
3. Siegel D, McGuinness SM, Winski SL, Ross D (1999) Genotypephenotype relationships in studies of a polymorphism in NAD (P) H: quinone oxidoreductase 1. Pharmacogenetics 9:113-121
4. Siegel D, Anwar A, Winski SL, Kepa JK, Zolman KL, Ross D (2001) Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD (P) H: quinone oxidoreductase 1. Mol Pharmacol 59:263-268
5. Siegel D, Ross D (2000) Immunodetection of NAD (P) H: quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic Biol Med 29:246-253
6. Koudstaal J, Makkink B, Overdiep SH (1975) Enzyme histochemical pattern in human tumours II. Oxidoreductases in carcinoma of the colon and the breast. Eur J Cancer 11:111-115
7. Schlager JJ, Powis G (1990) Cytosolic NAD (P) H: (quinoneacceptor) oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int J Cancer 45:403-409
8. Talalay P, Dinkova-Kostova AT (2004) Role of nicotinamide quinone oxidoreductase 1 (NQO1) in protection against toxicity of electrophiles and reactive oxygen intermediates. Methods Enzymol 382:355-364
9. Adikesavan AK, Barrios R, Jaiswal AK (2007) In vivo role of NAD (P) H: quinone oxidoreductase 1 in metabolic activation of mitomycin C and bone marrow cytotoxicity. Cancer Res 67:7966-7971
10. Asher G, Lotem J, Cohen B, Sachs L, Shaul Y (2001) Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc Natl Acad Sci USA 98:1188-1193
11. Asher G, Lotem J, Kama R, Sachs L, Shaul Y (2002) NQO1 stabilizes p53 through a distinct pathway. Proc Natl Acad Sci USA 99:3099-3104
12. Gong X, Kole L, Iskander K, Jaiswal AK (2007) NRH: quinone oxidoreductase 2 and NAD (P) H: quinone oxidoreductase 1 protect tumor suppressor p53 against 20 s proteasomal degradation leading to stabilization and activation of p53. Cancer Res 67:5380-5388
13. Ahn KS, Sethi G, Jain AK, Jaiswal AK, Aggarwal BB (2006) Genetic deletion of NAD (P) H: quinone oxidoreductase 1 abrogates activation of nuclear factor-kappaB, IkappaBalpha kinase, c-Jun. N-terminal kinase, Akt, p38, and p44/42 mitogen-activated protein kinases and potentiates apoptosis. J Biol Chem 281:19798-19808
14. Morgan MJ, Liu ZG (2011) Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res 21:103-115
15. Perkins ND, Gilmore TD (2006) Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ 13:759-772
16. Iskander K, Li J, Han S, Zheng B, Jaiswal AK (2006) NQO1 and NQO2 regulation of humoral immunity and autoimmunity. J Biol Chem 281:30917-30924
17. Siemankowski LM, Morreale J, Butts BD, Briehl MM (2000) Increased tumor necrosis factor-alpha sensitivity of MCF-7 cells transfected with NAD (P) H: quinone reductase. Cancer Res 60:3638-3644
18. Sethi G, Sung B, Aggarwal BB (2008) Nuclear factor-kappaB activation: from bench to bedside. Exp Biol Med 233:21-31
19. Mann AP, Verma A, Sethi G, Manavathi B, Wang H, Fok JY et al (2006) Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer Res 66:8788-8795
20. Kim DW, Sovak MA, Zanieski G, Nonet G, Romieu-Mourez R, Lau AW et al (2000) Activation of NF-kappaB/Rel occurs early during neoplastic transformation of mammary cells. Carcinogenesis 21:871-879
21. Frasor J, Weaver A, Pradhan M, Dai Y, Miller LD, Lin CY et al (2009) Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer. Cancer Res 69:8918-8925
22. Bradbury CM, Markovina S, Wei SJ, Rene LM, Zoberi I, Horikoshi N et al (2001) Indomethacin-induced radiosensitization and inhibition of ionizing radiation-induced NF-kappaB activation in HeLa cells occur via a mechanism involving p38 MAP kinase. Cancer Res 61:7689-7696
23. Montagut C, Tusquets I, Ferrer B, Corominas JM, Bellosillo B, Campas C et al (2006) Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients. Endocr Relat Cancer 13:607-616
24. Bottero V, Busuttil V, Loubat A, Magne N, Fischel JL, Milano G et al (2001) Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells. Cancer Res 61:7785-7791
25. Ho WC, Dickson KM, Barker PA (2005) Nuclear factor-kappaB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-kappaB-dependent transcription in cancer cells. Cancer Res 65:4273-4281
26. Syrjakoski K, Vahteristo P, Eerola H, Tamminen A, Kivinummi K, Sarantaus L et al (2000) Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 92:1529-1531
27. Kilpivaara O, Bartkova J, Eerola H, Syrjakoski K, Vahteristo P, Lukas J et al (2005) Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int J Cancer 113:575-580
28. Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J et al (2005) Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 11:5098-5103
29. Vehmanen P, Friedman LS, Eerola H, McClure M, Ward B, Sarantaus L et al (1997) Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet 6:2309-2315
30. Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O et al (2002) A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 71:432-438
31. Vahteristo P, Eerola H, Tamminen A, Blomqvist C, Nevanlinna H (2001) A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Br J Cancer 84:704-708
32. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403-410
33. Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart MJ et al (2000) Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 157:1467-1472
34. Lassus H, Leminen A, Vayrynen A, Cheng G, Gustafsson JA, Isola J et al (2004) ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol Oncol 92:31-39
35. Tommiska J, Bartkova J, Heinonen M, Hautala L, Kilpivaara O, Eerola H et al (2008) The DNA damage signalling kinase ATM is aberrantlyreducedorlostinBRCA1/BRCA2-deficientand ER/PR/ERBB2-triple-negative breast cancer. Oncogene 27:2501-2506
36. Ahlin C, Aaltonen K, Amini RM, Nevanlinna H, Fjallskog ML, Blomqvist C (2007) Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values? Histopathology 51:491-498
37. Sjostrom J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lonn S, Bengtsson NO et al (1999) Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35:1194-1201
38. Tynninen O, Sjostrom J, von Boguslawski K, Bengtsson NO, Heikkila R, Malmstrom P et al (2002) Tumour microvessel density as predictor of chemotherapy response in breast cancer patients. Br J Cancer 86:1905-1908
39. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207-214
40. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM et al (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23:9067-9072
41. Bartkova J, Horejsi Z, Sehested M, Nesland JM, Rajpert-De Meyts E, Skakkebaek NE et al (2007) DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours. Oncogene 26:7414-7422
42. Lessard L, Begin LR, Gleave ME, Mes-Masson A-M, Saad F (2005) Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer 93:1019-1023
43. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S et al (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5:R80
44. Du P, Kibbe WA, Lin SM (2008) lumi: a pipeline for processing Illumina microarray. Bioinformatics 24:1547-1548
45. Bolstad BM, Irizarry RA, Astrand M, Speed TP (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19:185-193
46. Tatusova T (2010) Genomic databases and resources at the National Center for Biotechnology Information. Methods Mol Biol 609:17-44
47. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc 57:289-300
48. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4:44-57
49. Verstrepen L, Bekaert T, Chau TL, Tavernier J, Chariot A, Beyaert R (2008) TLR-4, IL-1R and TNF-R signaling to NF-kappaB: variations on a common theme. Cell Mol Life Sci 65:2964-2978
50. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J et al (2006) Genome-wide analysis of estrogen receptor binding sites. Nat Genet 38:1289-1297
51. Jones RL, Rojo F, A'hern R, Villena N, Salter J, Corominas JM, et al. (2010) Nuclear NF-{kappa}B/p65 expression and response to neoadjuvant chemotherapy in breast cancer. J Clin Pathol 64:130-135
52. Gionet N, Jansson D, Mader S, Pratt MA (2009) NF-kappaB and estrogen receptor alpha interactions: differential function in estrogen receptor-negative and -positive hormone-independent breast cancer cells. J Cell Biochem 107:448-459
53. Cheng Y, Li J, Martinka M, Li G (2010) The expression of NAD (P) H: quinone oxidoreductase 1 is increased along with NF-kappaB p105/p50 in human cutaneous melanomas. Oncol Rep 23:973-979
54. Garate M, Wani AA, Li G (2010) The NAD (P) H: quinone oxidoreductase 1 induces cell cycle progression and proliferation of melanoma cells. Free Radic Biol Med 48:1601-1609
55. Hubackova M, Vaclavikova R, Mrhalova M, Kubackova K, Kodet R, Gut I et al (2009) NAD (P) H: quinone oxidoreductase 1 Pro187Ser polymorphism and expression do not cosegregate with clinico-pathological characteristics of human mammary tumors. Pharmacogenet Genomics 19:505-512
56. Sarbia M, Bitzer M, Siegel D, Ross D, Schulz WA, Zotz RB et al (2003) Association between NAD (P) H: quinone oxidoreductase 1 (NQ01) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract. Int J Cancer 107:381-386
57. Cleton-Jansen AM, van Eijk R, Lombaerts M, Schmidt MK, Van't Veer LJ, Philippo K et al (2008) ATBF1 and NQO1 as candidate targets for allelic loss at chromosome arm 16q in breast cancer: absence of somatic ATBF1 mutations and no role for the C609T NQO1 polymorphism. BMC Cancer 8:105
58. Jonsson G, Staaf J, Vallon-Christersson J, Ringner M, Holm K, Hegardt C et al (2010) Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res 12:R42